The latest price target for Champions Oncology (NASDAQ:CSBR) was reported by Craig-Hallum on September 12, 2024. The analyst firm set a price target for $6.00 expecting CSBR to rise to within 12 months (a possible 27.66% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Champions Oncology (NASDAQ:CSBR) was provided by Craig-Hallum, and Champions Oncology upgraded their buy rating.

The last upgrade for Champions Oncology Inc happened on September 12, 2024 when Craig-Hallum raised their price target to $6. Craig-Hallum previously had a hold for Champions Oncology Inc.

The last downgrade for Champions Oncology Inc happened on March 13, 2024 when Craig-Hallum changed their price target from N/A to N/A for Champions Oncology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Champions Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Champions Oncology was filed on September 12, 2024 so you should expect the next rating to be made available sometime around September 12, 2025.

While ratings are subjective and will change, the latest Champions Oncology (CSBR) rating was a upgraded with a price target of $6.00 to $6.00. The current price Champions Oncology (CSBR) is trading at is $4.70, which is out of the analyst’s predicted range.